<DOC>
	<DOCNO>NCT00570284</DOCNO>
	<brief_summary>The primary purpose study evaluate effect food oral LBH589 adult patient advance solid tumor . This study also evaluate safety efficacy LBH589 adult patient advance solid tumor</brief_summary>
	<brief_title>A Study Investigate Effect Food Oral LBH589 Absorption Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Inclusion criterion : Patients advance solid tumor whose disease progress despite standard therapy standard therapy exist Age ≥ 18 year old Patients must adequate laboratory value Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Ability swallow capsule tablet Exclusion criterion : Patients active central nervous system ( CNS ) disease brain metastasis except previously treat stable least 3 month . Patients second primary malignancy currently clinically significant require active intervention Impaired heart function clinically significant heart disease Impairment gastrointestinal ( GI ) function , GI disease may significantly alter absorption LBH589 Ongoing diarrhea Liver renal disease impair hepatic renal function Concomitant use anticancer therapy certain drug Female patient pregnant breast feed Patients willing use effective method birth control Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>solid tumor</keyword>
	<keyword>food effect</keyword>
	<keyword>HDAC inhibitor</keyword>
	<keyword>oral</keyword>
	<keyword>LBH589</keyword>
</DOC>